“…Accordingly, compound 3 had significant antibacterial activity against V. cholerae CO6, V. cholerae NB2, V. cholerae PC2, S. flexneri, and S. aureus while compound 6 had significant antibacterial activity against Shigella flexneri SDINT and Staphylococcus aureus ATCC 25923. The strains of V. cholerae NB2, PC2 (24,25) and Shigella flexneri (26) included in the present study were MDR clinical isolates and these were resistant to commonly used drugs such as ampicillin, streptomycin, tetracycline, nalidixic acid, furazolidone, and co-trimoxazole. However, most of the tested samples displayed antibacterial activity against these microbial strains, suggesting that their administration may represent an alternative treatment for V. cholerae, the cause of the dreadful disease cholera, and S. flexneri, the cause of shigellosis.…”